NL Health Services are going to partner with Swiss firm Lyfegen to streamline and improve the pharmaceutical rebate process for some oncology and other drug products.

NL Health holds confidential agreements, called product listing agreements, with pharmaceutical companies to fund specific drugs at a sustainable price through the use of a rebate process. Those arrangements allow NL Health to cover treatments which otherwise may not be affordable. Each agreement contains its own confidential terms achieved during the national negotiation process.

Ron Johnson, VP Innovation and Research at NL Health, says automating the process will decrease risk of error in cost calculation.